Skip to main content

Startup wants to reverse Parkinson’s and Alzheimer’s using human blood extract

A cutting-edge startup is working on a treatment for neurodegenerative diseases such as Parkinson’s and Alzheimer’s by altering the concentration of plasma proteins in patients. This work is based on previous research from Stanford University indicating that cognitive decline in mice can be reversed through injections of blood taken from younger mice.

“Alkahest recently announced the initiation of a Phase 2 trial of its proprietary human plasma fraction, GRF6021, for the treatment of Parkinson’s disease with associated mild cognitive impairment or dementia,” Steven Braithwaite, Chief Scientific Officer at Alkahest, told Digital Trends. “As humans age, there is change in the makeup of the proteins in plasma. Some of the key, function-driving plasma proteins increase or decrease with time. At Alkahest, we have termed these changing proteins ‘chronokines.’”

Recommended Videos

It is the loss of these beneficial chronokine proteins which are implicated with the onset of various age-related diseases through the reduction of regenerative properties that preserve biological functions. In previous studies, the human plasma fraction, GRF6021, has been shown to enhance neurogenesis, improve learning and memory, slow cognitive decline, reduce inflammation, and preserve cell health in animal models.

Please enable Javascript to view this content

In Alkahest’s new trial, 90 Parkinson’s patients, mostly in their 70s and 80s, will receive multiple injections containing GRF6021. This plasma fraction is extracted from blood taken from blood banks, with an average donor age of 32. Over the course of the study, the participants will be tested for signs of improved memory, attention, language skills, and more.

“We believe that GRF6021’s unique properties grants the candidate a potential mechanistic advantage over currently available and clinical-stage therapies, whose mode of action typically targets one symptom of disease — and for the most part are ineffective at addressing the complex root causes of disease and aging,” Braithwaite continued.

After the completion of this trial in 2020, Alkahest next plans to advance GRF6021 into larger Phase 3 trials. The company has also carried out trials involving a second proprietary plasma protein fraction, GRF6019, in Alzheimer’s patients.

“In preclinical trials, both products reversed age and disease-related cognitive decline,” Karoly Nikolich, CEO of Alkahest, told us. “We are currently studying GRF6019 in an ongoing Phase 2 trial in mild to moderate Alzheimer’s disease patients. Based on the promise of what we have observed in earlier preclinical and clinical trials, Alkahest will also be initiating a Phase 2 trial in severe Alzheimer’s patients planned for initiation in the first half of 2019.”

Luke Dormehl
Former Digital Trends Contributor
I'm a UK-based tech writer covering Cool Tech at Digital Trends. I've also written for Fast Company, Wired, the Guardian…
Hyundai Ioniq 5 sets world record for greatest altitude change
hyundai ioniq 5 world record altitude change mk02 detail kv

When the Guinness World Records (GWR) book was launched in 1955, the idea was to compile facts and figures that could finally settle often endless arguments in the U.K.’s many pubs.

It quickly evolved into a yearly compilation of world records, big and small, including last year's largest grilled cheese sandwich in the world.

Read more
Global EV sales expected to rise 30% in 2025, S&P Global says
ev sales up 30 percent 2025 byd sealion 7 1stbanner l

While trade wars, tariffs, and wavering subsidies are very much in the cards for the auto industry in 2025, global sales of electric vehicles (EVs) are still expected to rise substantially next year, according to S&P Global Mobility.

"2025 is shaping up to be ultra-challenging for the auto industry, as key regional demand factors limit demand potential and the new U.S. administration adds fresh uncertainty from day one," says Colin Couchman, executive director of global light vehicle forecasting for S&P Global Mobility.

Read more
Faraday Future could unveil lowest-priced EV yet at CES 2025
Faraday Future FF 91

Given existing tariffs and what’s in store from the Trump administration, you’d be forgiven for thinking the global race toward lower electric vehicle (EV) prices will not reach U.S. shores in 2025.

After all, Chinese manufacturers, who sell the least expensive EVs globally, have shelved plans to enter the U.S. market after 100% tariffs were imposed on China-made EVs in September.

Read more